Galectin-3: therapeutic targeting in liver disease

Mackinnon, Alison C.; Tonev, Dimitar; Jacoby, Brian; Pinzani, Massimo; Slack, Robert J.

doi:10.1080/14728222.2023.2258280

Cited by 9 publications

(1 citation statement)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown that galectin is associated with the physiopathology of various chronic liver disease ( Jeng et al, 1994 ; Sano et al, 2000 ). Currently, galectin is considered a potential target for the early treatment of many liver diseases as it directly activates NLRP3 inflammatory vesicles, which play a key role in liver fibrosis ( Mackinnon et al, 2023 ). Psat1 (Uniprot ID: A0A0G2K931) and Phgdh (Uniprot ID: O08651) are critical enzymes involved in the de novo synthesis of serine, directing the glycolytic intermediate 3-phosphoglyceric acid into the pathway.…”

Section: Discussionmentioning

confidence: 99%

Label-free proteomic analysis reveals the hepatoprotective mechanism of gypenosides in liver injury rats

Chen,

Ma,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Chronic liver disease, a long-term condition resulting from various causes such as alcohol abuse, metabolic disorders, and viral hepatitis, is becoming a significant global health challenge. Gypenosides (GPs), derived from the traditional Chinese medicine Gynostemma pentaphyllum (Thunb.) Makino, exhibited hepatoprotective properties in recent years, yet the precise therapeutic mechanism remains unclear. In this study, label-free and parallel reaction monitoring (PRM) proteomics were used to elucidate the hepatoprotective mechanism of GPs in liver injury rats. Through label-free proteomics, we identified 2104 differentially expressed proteins (DEPs) associated with liver injury, along with 1974 DEPs related to the effects of GPs. Bioinformatics analysis revealed that GPs primarily restored metabolic processes involving valine, leucine, and isoleucine degradation, as well as propanoate and butanoate metabolism, and steroid hormone biosynthesis during liver injury. Subsequently, overlapping the two groups of DEPs identified 1508 proteins reversed following GPs treatment, with key targets further validated by PRM. Eight target proteins were identified for GPs treatment of liver injury, including Lgals3, Psat1, Phgdh, Cyp3a9, Cyp2c11, Cyp4a2, Glul, and Ces1d. These findings not only elucidated the hepatoprotective mechanism of GPs, but may also serve as potential therapeutic targets of chronic liver disease.

show abstract

Section: Discussionmentioning

confidence: 99%